JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Support: [email protected]

Track Your Order

c-MET

A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A5703 BMS-777607

Target: MET

Summary: C-Met inhibitor, potent and selective

≥25.65 mg/mL
A5096 PF-04217903

Target: c-MET

Summary: C-Met inhibitor,selective and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥18.6 mg/mL
A5092 JNJ-38877605

Summary: C-Met inhibitor,ATP-competitive

insoluble in H2O; ≥18.85 mg/mL
A3847 SU5416
7 Citation

Target: VEGFR

Summary: VEGFR2 inhibitor

insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL
A3712 PF-04217903 methanesulfonate

Target: c-MET

Summary: C-Met inhibitor,selective and ATP-competitive

Soluble in DMSO
A3624 MK-8033

Summary: C-MET inhibitor

Soluble in DMSO
A3573 LY2801653

Target: MET

Summary: MET inhibitor

≥27.65 mg/mL
A3020 (R)-Crizotinib
3 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
A2977 Cabozantinib (XL184, BMS-907351)

Summary: VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor

≥25.08 mg/mL